Publications

5898 Results

S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula

Authors
J Sham;V Pillarisetty;K Guthrie;K Arnold;R Topacio;K Carvalho;G Wright;V Sun;F Rocha;S Ahmad;R Krouse
Journal / Conference
ASCO GI Cancers Symposium (January 8 - 10, 2026, San Francisco, CA); J Clin Oncol 44, TPS790(2026); DOI: 10.1200/JCO.2026.44.2_suppl.TPS790
Year
2026
Research Committee(s)
Palliative Care
Study Number(s)
S2408

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714

Authors
M Trivedi;J Unger;NL Henry;A Darke;D Hertz;T Brannagan;S Reyes;B Schneider;W Irvin;A Hathaway;A Vander Woude;V Gudena;P Cabrera-Galeana;M Orsted;M LeBlanc;M Fisch;D Hershman
Journal / Conference
JAMA Network Open. 2026 Apr 1;9(4):e264901. doi: 10.1001/jamanetworkopen.2026.4901.
Year
2026
Research Committee(s)
Symptom Management and Survivorship
PMID
41961500
PMC
PMC13069458
Study Number(s)
S1714

Long-Term Follow-up of an Intensive Pediatric Regimen for Adolescents/Young Adults with Ph-negative Acute Lymphoblastic Leukemia: 10-year Survival Following CALGB 10403 (Alliance)

Authors
W Silva;V Yin;M Liedtke;D Claxton;N Fulton;S Giri;G Malnassy;K Mrozek;E Paietta;C Mullighan;RA Larson;R Stone;G Uy;S Luger;A Advani;W Stock
Journal / Conference
Blood Advances 2026 May 8:bloodadvances.2026019616. doi: 10.1182/bloodadvances.2026019616
Year
2026
Research Committee(s)
Leukemia
PMID
42101912
Study Number(s)
C10403

Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study

Authors
P Gupta;K Gupta;T Dockter;E Harlos;S Chow;N Subbiah;K Ruddy;L Bazhenova;S Terstriep;C Huang;R Kratzke;E Vokes;C Loprinzi
Journal / Conference
Cancers (Basel). 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373.
Year
2026
Research Committee(s)
Symptom Management and Survivorship
PMID
41681846
PMC
PMC12896856
Study Number(s)
CTSU/A221504

DART/SWOG/NCI phase II anti- CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix

Authors
Y Chae;M Othus;S Patel;F Backes;D O'Malley;M Cristea;A Naing;K Kurnit;R Eskander;S Goodrich;W Robinson;H Kim;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock
Journal / Conference
Journal for the ImmunoTherapy of Cancer 2026 Feb 11. 14:e012805. doi:10.1136/jitc-2025-012805.
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
41672597
Study Number(s)
S1609

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective from Lung-MAP Investigators

Authors
D Doroshow;TBA
Journal / Conference
Journal of Clinical Oncology. 2026 June 3 epub. DOI: 10.1200/JCO-25-01896
Year
2026
Research Committee(s)
Lung
PMID
42234933
Study Number(s)
LUNGMAP

Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;R Puri;A Mitra;T Home;J Gralow;K Albain;D Hayes;S Delaloge;N Lin;E Perez;L Goldstein;S Chia;P Rastogi;A Schott;S Shak;D Tripathy;G Hortobagyi;F Meric-Bernstein;P Sharma;L Pusztai;A Thompson;H Pathak;A Godwin
Journal / Conference
Annals of Oncology
Year
2026
Research Committee(s)
Breast
PMID
13488494
PMC
PMC42613139
Study Number(s)
S1007

Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer

Authors
R Jagsi;A Meisner;P Chalasani;W Barlow;J Bellon;NL Henry;D Lew;M Matusak;J Moran;L Pierce;E Rakovitch;S Reyes;C Speers;J Unger;J White;W Woodward;R Zellars;L Pusztai;P Sharma
Journal / Conference
Int J Radiat Oncol Biol Phys. 2026 Jul 28:S0360-3016(26)04066-6.
Year
2026
Research Committee(s)
Breast
PMID
42520859
Study Number(s)
S1706

Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007)

Authors
Y Abdou;J Hoag;W Barlow;K Albain;J Gralow;F Meric-Bernstam;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;A Schott;J Racz;FL Baehner;D Tripathy;G Hortobagyi;L Pusztai;P Sharma;K Kalinsky
Journal / Conference
J Natl Cancer Inst . 2026 Jul 15:djag221. doi: 10.1093/jnci/djag221
Year
2026
Research Committee(s)
Breast
PMID
42458791
Study Number(s)
S1007

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner

Authors
A Zadoroznyj;P Eriksson;C Bernardo;?? L Tran;CA Mattsson;T Flaig;C Tangen;S Lerner;D McConkey;M Hoglund;F Leidberg;G Sjodahl
Journal / Conference
NPJ Precision Oncology 2026 Jul 3;10(1):258. doi: 10.1038/s41698-026-01588-7.
Year
2026
Research Committee(s)
Genitourinary
PMID
42399473
PMC
PMC13332042
Study Number(s)
S1314